[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alpha Tau Medical Ltd Cl A (DRTS)

Alpha Tau Medical Ltd Cl A (DRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 883,388
  • Shares Outstanding, K 90,326
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,630 K
  • EBIT $ -13 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.41

Options Overview Details

View History
  • Implied Volatility 101.34% (-15.70%)
  • Historical Volatility 106.87%
  • IV Percentile 27%
  • IV Rank 3.28%
  • IV High 812.34% on 12/09/25
  • IV Low 77.26% on 05/05/26
  • Expected Move (DTE 27) 2.00 (20.42%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 680
  • Volume Avg (30-Day) 1,474
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 19,844
  • Open Int (30-Day) 16,493
  • Expected Range 7.78 to 11.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 2
  • High Estimate $-0.14
  • Low Estimate $-0.14
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.75 +11.77%
on 06/09/26
11.62 -15.83%
on 05/20/26
-0.25 (-2.49%)
since 05/18/26
3-Month
6.35 +54.00%
on 03/30/26
11.62 -15.83%
on 05/20/26
+2.47 (+33.79%)
since 03/18/26
52-Week
2.85 +243.16%
on 06/23/25
11.62 -15.83%
on 05/20/26
+6.87 (+236.07%)
since 06/18/25

Most Recent Stories

More News
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven...

DRTS : 9.78 (+1.77%)
DRTSW : 1.9600 (-0.76%)
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the U.S. uro-oncology landscape  - Collaboration...

DRTS : 9.78 (+1.77%)
DRTSW : 1.9600 (-0.76%)
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of...

DRTS : 9.78 (+1.77%)
DRTSW : 1.9600 (-0.76%)
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears

Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company’s...

DRTS : 9.78 (+1.77%)
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion...

DRTS : 9.78 (+1.77%)
DRTSW : 1.9600 (-0.76%)
Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 9.78 (+1.77%)
DRTSW : 1.9600 (-0.76%)
Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...

DRTS : 9.78 (+1.77%)
Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...

DRTS : 9.78 (+1.77%)
Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...

DRTS : 9.78 (+1.77%)
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study

Alpha Tau Medical (NASDAQ:DRTS) presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical...

DRTS : 9.78 (+1.77%)

Business Summary

Alpha Tau Medical Ltd. is a medical device company. It focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha Tau Medical Ltd., formerly known as Healthcare Capital Corp., is based in JERUSALEM.

See More

Key Turning Points

3rd Resistance Point 10.92
2nd Resistance Point 10.56
1st Resistance Point 10.17
Last Price 9.78
1st Support Level 9.42
2nd Support Level 9.06
3rd Support Level 8.67

See More

52-Week High 11.62
Last Price 9.78
Fibonacci 61.8% 8.27
Fibonacci 50% 7.23
Fibonacci 38.2% 6.20
52-Week Low 2.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.